Calmare Therapeutics Analysis
| CTTCDelisted Stock | USD 0.0001 0.00 0.00% |
Calmare Therapeutics is overvalued with Real Value of 9.5E-5 and Hype Value of 1.25E-4. The main objective of Calmare Therapeutics delisted stock analysis is to determine its intrinsic value, which is an estimate of what Calmare Therapeutics is worth, separate from its market price. There are two main types of Calmare Therapeutics' stock analysis: fundamental analysis and technical analysis.
The Calmare Therapeutics stock is traded in the USA on OTCCE Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Here, you can get updates on important government artifacts, including earning estimates, SEC corporate filings, announcements, and Calmare Therapeutics' ongoing operational relationships across important fundamental and technical indicators.
Calmare |
Calmare Stock Analysis Notes
The company recorded a loss per share of 0.13. Calmare Therapeutics had not issued any dividends in recent years. The entity had 3:2 split on the 17th of March 1981. Calmare Therapeutics Incorporated, a medical device company, develops and commercializes products and technologies for chronic neuropathic pain and wound care affliction patients in the United States. Calmare Therapeutics Incorporated was founded in 1968 and is based in Fairfield, Connecticut. Calmare Therapeutics operates under Medical Devices classification in the United States and is traded on NYSEMKT Exchange. It employs 7 people. For more info on Calmare Therapeutics please contact Conrad Mir at 203-368-6044 or go to http://www.calmaretherapeutics.com.Calmare Therapeutics Investment Alerts
Many investors view ongoing market volatility as an opportunity to purchase more delisted stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Calmare Therapeutics' investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Calmare Therapeutics or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
| Calmare Therapeutics is not yet fully synchronised with the market data | |
| Calmare Therapeutics has some characteristics of a very speculative penny stock | |
| Calmare Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| The company has a current ratio of 0.22, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Note, when we think about Calmare Therapeutics' use of debt, we should always consider it together with its cash and equity. | |
| Calmare Therapeutics reported the previous year's revenue of 1.17 M. Net Loss for the year was (3.83 M) with profit before overhead, payroll, taxes, and interest of 771.48 K. | |
| Calmare Therapeutics currently holds about 12.55 K in cash with (1.24 M) of positive cash flow from operations. |
Calmare Market Capitalization
The company currently falls under 'Nano-Cap' category with a current market capitalization of 11.09 K.Calmare Therapeutics Outstanding Bonds
Calmare Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Calmare Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Calmare bonds can be classified according to their maturity, which is the date when Calmare Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| Volcan Compania Minera Corp BondUSP98047AC08 | View | |
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| MPLX LP 4875 Corp BondUS55336VAG59 | View | |
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| Morgan Stanley 3591 Corp BondUS61744YAK47 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View |
Calmare Therapeutics Predictive Daily Indicators
Calmare Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Calmare Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
| Rate Of Daily Change | 1.0 | |||
| Day Median Price | 1.0E-4 | |||
| Day Typical Price | 1.0E-4 |
About Calmare Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how Calmare Therapeutics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Calmare shares will generate the highest return on investment. We also built our delisted stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Delisted Stock such as Calmare Therapeutics. By using and applying Calmare Stock analysis, traders can create a robust methodology for identifying Calmare entry and exit points for their positions.
Calmare Therapeutics Incorporated, a medical device company, develops and commercializes products and technologies for chronic neuropathic pain and wound care affliction patients in the United States. Calmare Therapeutics Incorporated was founded in 1968 and is based in Fairfield, Connecticut. Calmare Therapeutics operates under Medical Devices classification in the United States and is traded on NYSEMKT Exchange. It employs 7 people.
Be your own money manager
As an investor, your ultimate goal is to build wealth. Optimizing your investment portfolio is an essential element in this goal. Using our stock analysis tools, you can find out how much better you can do when adding Calmare Therapeutics to your portfolios without increasing risk or reducing expected return.Did you try this?
Run Portfolio Volatility Now
Portfolio VolatilityCheck portfolio volatility and analyze historical return density to properly model market risk |
| All Next | Launch Module |
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the Bonds Directory module to find actively traded corporate debentures issued by US companies.
Other Consideration for investing in Calmare Stock
If you are still planning to invest in Calmare Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Calmare Therapeutics' history and understand the potential risks before investing.
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk |